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Abstract
Canine leishmaniosis is a severe systemic disease caused by the kinetoplastid protozoan Leishmania
infantum, an obligatory intracellular parasite of mammalian macrophages, transmitted by the bite of
phlebotomine sandflies. The infection in dogs might occur without any clinical signs or might be
characterised by chronic viscerocutaneous signs, such as lymphadenopathy, skin lesions,
splenomegaly, onychogryphosis, and renal as well as ocular damage due to immunocomplex
deposition. In atypical cases the parasites can be found in the striated musculature, the central
nervous system, the endocrine glands or gonads, with or without functional damage. Leishmania
infection might seldom induce oral lesions, particularly on the tongue.The authors describe the
clinical case of a four-year old mongrel dog with tongue lesions caused by L. infantum.The dog was
presented due to diarrhoea, lack of appetite and hypersalivation. Examination of the oral cavity
revealed the presence of multiple red, nodular lesions on the dorsal and lateral surfaces of the
tongue. Definite diagnosis of an infection with L. infantum was obtained by an indirect immuno-
fluorescence antibody test (IFAT) and by the cytological identification of the parasite in nodular,
lingual lesions and bone marrow aspirates.The dog was treated with a combination of miltefosine
(Milteforan®, Virbac), 2 mg/kg orally once a day for four weeks and allopurinol (Ziloric®,
GlaxoSmithKline), 10 mg/kg orally twice a day for six months. At the end of the treatment, the
animal showed full remission of clinical signs.The authors outline the atypical manifestations in the
oral cavity in combination with a L. infantum infection and discuss the therapeutic potential of the
combination treatment of miltefosine and allopurinol in canine leishmaniosis.
Open Access
Findings
L. infantum is an obligatory intracellular parasite of
mammalian macrophages transmitted by phlebotomine
sandflies of the genus Phlebotomus (Old World) and
Lutzomyia (New World). It is a heteroxenous parasite, i.e.
it needs two hosts to develop. On the vertebrate side, the
principal hosts of L. infantum are dogs and other members
of the Canidae family (foxes, jackals, wolves). In Italy,
Phlebotomus perniciosus is considered the main species
responsible for the dispersion of the infection [1]. The
disease is endemic in the Mediterranean basin, Asia and
Latin America, but is also reported in a rising number of
cases from non-endemic countries due to pet travel and
import [2,3]. In Italy, CanL has been observed for long
time only in southern, central and the insular regions [4].
Recently, there has been evidence that CanL is currently
expanding to north-western Italy into areas with a
continental climate, far away from the recognised
endemic areas along the Mediterranean coast [5]. Parasite
transmission occurs through the bite of an infected
phlebotomine sandfly, although secondary modes of
transmission (e.g. via blood transfusion and congenital
transmission) have been suggested [6,7].
Clinically, CanL is characterised by chronic viscero-
cutaneous signs, such as lymphadenopathy, skin lesions
(furfuraceus dermatitis, ulcers and nodular lesions),
symmetrical alopecia [8], keratoconjunctivitis, epistaxis
and diarrhoea [9]. In atypical cases the parasites can also
be found in the striated musculature, the central nervous
system and the endocrine glands or gonads, with or
without functional damage [10]. Mucosal localizations
are rarely described in dog [11-14]. All known anti-
Leishmania drugs used for CanL therapy can lead to
temporary or permanent remission of clinical signs, but
none of them is sufficient to eradicate the infection from
diseased dogs [15]. Nonetheless, chemotherapy does not
guarantee parasitological healing, the cessation of
infectivity to sandfly vectors feeding on the canine host
and/or the prevention of clinical relapse. The most
commonly used drugs against CanL are the parenteral
pentavalent antimonial meglumine antimoniate and the
oral purine analogue allopurinol. These two medications
are frequently used in combination [16]. Pentavalent
antimonials have to be administered for a period ranging
between 4 and 8 weeks. Allopurinol is usually adminis-
tered for several months after clinical stabilization has
been obtained.
There are a number of reasons that provoke the decision
to choose an alternative protocol to the first-line drug
combination of meglumine antimoniate and allopurinol.
Among others these are unresponsiveness to therapy,
severe side effects, occurrence of frequent relapses, poor
owner’s compliance to mode and frequency of drug
administration and the possible selection of drug
resistant strains of L. infantum. Other drugs reported to
have some efficacy against CanL include miltefosine,
pentamidine, aminosidine (paromomycin), ketoconazole,
metronidazole with spyramicin, marbofloxacin and
domperidone. Howevermore extensive clinical studies are
necessary to verify their therapeutic effectiveness. Very
recently a combination between miltefosine and allo-
purinol was proposed as alternative protocol for the
treatment of CanL [17].
In the following, a case report of a L. infantum infected
dog with atypical lesions in the oral cavitiy, successfully
treated with miltefosien and allopurinol is given. A four-
year old mongrel dog was referred in March 2008 to the
Department of Clinical Science, University of Naples
(Italy), presenting a lack of appetite, diarrhoea and
hypersalivation, together with the presence of multiple
nodular lesions on the tongue. Clinical examination
showed a slight lymphadenomegaly. Exploration of the
oral cavity revealed the presence of multiple red, nodular
lesions on the dorsal and lateral surfaces of the tongue
(Figure 1). The following laboratory parameters were
examined: complete blood count, total plasma protein,
albumin/globulin ratio, urea, creatinine, alanine amino
transferase (ALT) and complete urine analyses. All
parameters were within the physiological range.
Cytological examination of lingual nodular lesions
demonstrated the presence of numerous neutrophils,
macrophages, epithelial cells and lymphocytes. Leishmania
amastigotes were detected within and outside macro-
phages (Figure 2). When examined by an indirect
immunofluorescence antibody test (IFAT) for L. infantum,
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Figure 1
Multiple red, nodular lesions on the dorsal and lateral
surfaces of the tongue.
the dog was positive,showing a titre of 1:1280. Cytology
of bone marrow-stained smears revealed a number of
Leishmania amastigotes.
The dog was treated with a combination of miltefosine
(Milteforan®, Virbac), at a dosage of 2 mg/kg body weight
orally once a day for four weeks and allopurinol (Ziloric®,
GlaxoSmithKline), at 10 mg/kg body weight orally twice a
day for six months. A good improvement of the systemic
clinical signs was observed at the end of the miltefosine
administration at four weeks, together with a partial
resolution of the tongue lesions. The almost dis-
appearance of the nodular tongue lesions was obtained
after two months from the beginning of the therapy
(Figure 3). Repeated haematological, biochemical and
urine analyses proved again to be in the physiological
range. The IFAT titre was recorded at 1:640. Cytological
examination of tongue aspirates did not show any
Leishmania amastigotes.
Zoonotic visceral leishmaniosis is the most widespread
entity of zoonotic leishmaniosis caused by a single
parasite species, L. infantum. Mucosal lesions caused by L.
infantum are not often reported in dogs. In humans, oral
lesions caused by L. infantum are not very common and
usually observed in severely immunosuppressed patients
(HIV co-infected patients, graft recipients [18]), though a
case of an immunocompetent patient affected by
leishmaniosis, characterized by a single lingual nodule
and several palatine nodular lesions, has been described
[19]. Oral Leishmania lesions, particularly on the tongue,
are very rarely reported in dogs [12-14]. Tongue lesions in
dogs are a probably the consequence of a systemic
dissemination of the parasite [12]. Very rarely, it was also
hypothesised that Leishmania-induced glossitis could
represent a localised mucosal leishmaniosis, resulting
from a new infection [13]. The above-described case
confirms the possibility that L. infantum can be localised
in the tongue tissue also in a dog without severe
immunological depression. In this dog, due to the
contemporary systemic involvement, showed by lymph
node enlargement and bone marrow parasite dissemi-
nation, lingual lesions could probably result from an
atypical dissemination of Leishmania parasites. The
clinical condition determined the necessity of an anti-
Leishmania drug therapy with leishmanicidal and systemic
properties. Miltefosine, originally developed as an anti-
cancer agent in humans [20] and registered for the
treatment of human visceral leishmaniosis, has recently
also been registered (Milteforan®) for the oral treatment
of canine leishmaniosis in several European countries.
The parasitological and clinical effectiveness of
miltefosine has been documented in humans and rodents
for many years [21,22]. With its direct anti-parasitic
activity not depending on a functional immune system,
its ease of use due to oral administration, and its low
toxicity, miltefosine seems to meet all the requirements
for a new drug to treat CanL. A potentially severe limita-
tion for this oral agent could be the early development of
drug resistance due to its long half-life [23]. To minimize
the danger of generating resistance in Leishmania strains,
it would be desirable to treat dogs and humans by
different drugs, a suggestion hardly practicable with the
drugs available at the moment.
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Figure 2
Free amastigote form of Leishmania sp. in cytological
material from the lingual lesions (May-Grünwald-Giemsa
Quick; x 1000; bar = 25 μm).surfaces of the tongue.
Figure 3
Almost clinical resolution of the tongue lesions after
treatment with a combination of miltefosine and allopurinol.
Up to now, only few studies have been carried out in dogs
with promising preliminary results. A recent study clearly
demonstrated that miltefosine combined with allopurinol
has clinical and parasitological effectiveness very similar to
the combination of antimonials and allopurinol [17]. The
association between these two drugs could have two
beneficial effects, in terms of the potentiation of efficacy
and the possible limitation of drug resistance. In the
absence of definitive data about the new drug
combination, our decision for this protocol was due to the
easier oral administration of the two drugs. The complete
clinical resolution of the above reported case and the
absence of side effects confirm the safety and the promising
efficacy of the combination between miltefosine and
allopurinol for the treatment of CanL, even for the
resolution of atypical localizations of the parasite.
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